3 Things In Biotech, August 3: Bristol Assaults Melanoma In Europe Again [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
Summary Welcome to another edition of 3 Things In Biotech, a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Bristol-Myers marches on in European melanoma care Company: Bristol-Myers Squibb ( BMY ) Therapy: Nivolumab Disease: Melanoma News: BMY announced that the EMA has approved its PD-1 inhibitor nivolumab in the setting of adjuvant therapy for melanoma after a complete resection. Patients can receive this treatment regardless of their BRAF mutational status. The approval was based on findings from the CheckMate-238 study, which demonstrated a significant improvement for nivolumab over ipilimumab in the adjuvant setting in terms of recurrence-free survival. Looking forward: Another small cog in the machine that BMY continues to build up. Obviously losing the top sales spot to Merck ( MRK ) wasn't going to slow its roll, and these supplemental approvals are one important way of cont
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol-Myers Squibb Company Non-GAAP EPS of -$4.40 beats by $0.02, revenue of $11.78B beats by $330M [Seeking Alpha]Seeking Alpha
- Bristol Myers Squibb Reports First Quarter Financial Results for 2024Business Wire
- Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Overhaul Unites Supply Chain Leaders with New Partner Ecosystem Program to Combat Global Cargo Theft [Yahoo! Finance]Yahoo! Finance
- The Galien Foundation Announces 2024 Prix Galien International Awards Nominees [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- BMY's page on the SEC website